Zobrazeno 1 - 10
of 30
pro vyhledávání: '"M. Shunmugavelu"'
Autor:
Subhash Wangnoo, M. Shunmugavelu, Sagili Vijaya Bhaskar Reddy, Vijay Negalur, Shreerang Godbole, Vinay K Dhandhania, Nareen Krishna, Kumar Gaurav
Publikováno v:
Endocrine and Metabolic Science, Vol 4, Iss , Pp 100102- (2021)
Navigating safely towards euglycemia in type 2 diabetes mellitus (T2DM) is a real challenge in the current clinical practice despite availability of a number of glucose-lowering drugs; major barriers are hypoglycemia and weight gain. Sulfonylureas (S
Externí odkaz:
https://doaj.org/article/5f007281cefa444db209778ee9998e03
Publikováno v:
Clinical Diabetology. 10:412-419
Real-world evidence can generate credible evidence to inform treatment decisions. Real-world evidence is in developmental stage and is fast evolving yet there are many unexplained attributes of real-world evidence. Real-world evidence informs benefit
Autor:
Ambrish Mithal, Debashish Majhi, M Shunmugavelu, Pradeep G Talwarkar, Hardik Vasnawala, Ammar S Raza
Publikováno v:
Indian Journal of Endocrinology and Metabolism, Vol 18, Iss 5, Pp 642-647 (2014)
Context: India leads the world with largest number of diabetic patients and is often referred to as the diabetes capital of the world. Diabetic dyslipidemia in India is one of the main cause for Coronary Artery Disease (CAD) mortality. Although diabe
Externí odkaz:
https://doaj.org/article/30919d63622440f3a5356ce83408fa57
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Vinay K Dhandhania, Subhash Kumar Wangnoo, Sagili Vijaya Bhaskar Reddy, Vijay Negalur, Nareen Krishna, M Shunmugavelu, Kumar Gaurav, Shreerang Godbole
Publikováno v:
Endocrine and Metabolic Science, Vol 4, Iss, Pp 100102-(2021)
Navigating safely towards euglycemia in type 2 diabetes mellitus (T2DM) is a real challenge in the current clinical practice despite availability of a number of glucose-lowering drugs; major barriers are hypoglycemia and weight gain. Sulfonylureas (S
Autor:
Brij Makkar, Manoj Chawla, Sunil Gupta, Rajeev Chawla, Sailesh Lodha, Anil Bhansali, Abhay Kumar Sahoo, M. Shunmugavelu, Sujoy Majumdar
Publikováno v:
Clinical Diabetology. 8:176-194
This consensus statement aimed to provide a simple and easily implementable practical educational guide- line for healthcare professionals (HCPs) and patients regarding insulin injection practice in diabetes self- management in the Indian setting. A
Autor:
AG Unnikrishnan, Kaushik Ramaiya, Sanjay Kalra, Ahmed Reja, Raquel Faradji, Noel Somasundaram, Joel Rodriguez-Saldana, Deep Dutta, Jubbin Jagan Jacob, M. Shunmugavelu, Abdurezak Ahmed Abdela, Md. Faruqe Pathan, Vineet Surana, Mangesh Tiwaskar, Leszek Czupryniak, Gagan Priya, Deepak Khandelwal, Khalid Shaikh, A. K. Das, Sundeep Ruder, Tint Swe Latt, G. Vijayakumar, Banshi Saboo, Fatema Jawad, Jyoti Bhattarai, Armindo Tiago, Manoj Chawla, Ankia Coetzee, Than Than Aye, Andrew E Uloko, Silver Bahendeka, Charlotte M Bavuma, Manilka Sumanathilaka, Sandeep Chaudhary, Pradip Krishna Shrestha, Ameya Joshi, Sambit Das, Subhankar Chowdhury, Bishwajit Bhowmik, Rakesh Sahay, Sarita Bajaj, Zhanay Akanov, Manash P Baruah, Abbas Raza, Roberta Lamptey
Publikováno v:
Diabetes Therapy
The past three decades have seen a quadruple rise in the number of people affected by diabetes mellitus worldwide, with the disease being the ninth major cause of mortality. Type 2 diabetes mellitus (T2DM) often remains undiagnosed for several years
Publikováno v:
Diabetes Research and Clinical Practice. 127:10-20
Introduction Diabetes mellitus (DM) is one of the leading causes of chronic kidney disease (CKD) which eventually leads to insulin resistance and decreased insulin degradation. In patients with diabetic kidney disease (DKD), the overall insulin requi
Autor:
Ganapathi, Bantwal, Subhash K, Wangnoo, M, Shunmugavelu, S, Nallaperumal, K P, Harsha, Arpandev, Bhattacharyya
Publikováno v:
The Journal of the Association of Physicians of India. 63
Insulin degludec/insulin aspart (IDegAsp) is the first soluble coformulation combining a long-acting insulin degludec (IDeg) and rapid-acting insulin aspart (IAsp). In patients with uncontrolled type 2 diabetes (T2DM) previously treated with insulins
Autor:
Hardik Vasnawala, Ambrish Mithal, Pradeep G Talwarkar, M Shunmugavelu, Debashish Majhi, Ammar Raza
Publikováno v:
Indian Journal of Endocrinology and Metabolism, Vol 18, Iss 5, Pp 642-647 (2014)
Indian Journal of Endocrinology and Metabolism
Indian Journal of Endocrinology and Metabolism
Context: India leads the world with largest number of diabetic patients and is often referred to as the diabetes capital of the world. Diabetic dyslipidemia in India is one of the main cause for Coronary Artery Disease (CAD) mortality. Although diabe